Part I | Chapter 6 126 BL vs. 12M p-value (ES) 0.021 (0.49) NA 0.106 (0.36) 0.032 (0.47) 0.366 (0.17) 0.141 (0.61) 0.248 (0.18) 0.434 (0.12) 0.345 (0.09) 0.968 (< 0.01) 0.999 (0.03) 0.295 (0.14) 0.850 (< 0.01) 12 months Median (IQR) 16.6 (11.4-26.1) 16.5 (8.3-24.8) 0.0 (0.0-8.3) 11.2 (5.5-22.2) 16.5 (0.0-33.0) 50.0 (41.5-79.3) 83.3 (66.7-83.3) 100.0 (89.2-100.0) 100.0(75.0-100.0) 100.0 (83.3-100.0) 0.0 (0.0-27.8) 0.0 (0.0-16.7) 0.0 (0.0-0.0) n 24 2 25 24 27 10 31 31 31 31 31 31 31 BL vs. 6M p-value (ES) 0.145 (0.30) 0.999 (0.71) 0.074 (0.36) < 0.001 (0.68) < 0.001 (0.58) 0.025 (0.82) 0.123 (0.18) 0.013 (0.42) 0.024 (0.28) 0.848 (0.07) 0.032 (0.32) 0.122 (0.12) 0.999 (< 0.01) 6 months Median (IQR) 12.4 (8.3-25.0) 0.0 (0.0-16.5) 0.0 (0.0-8.3) 16.5 (11.0-22.2) 0.0 (0.0-16.5) 50.0 (41.5-58.3) 83.3 (75.0-87.5) 93.3 (86.7-100.0) 100.0 (66.7-100.0) 100.0 (83.3-100.0) 11.1 (0.0-33.0) 0.0 (0.0-16.7) 0.0 (0.0-0.0) n 37 7 36 33 40 11 47 47 47 47 47 47 47 BL vs. 3M p-value (ES) 0.130 (0.29) 0.999 (0.58) 0.025 (0.40) 0.003 (0.61) < 0.001 (0.55) 0.246 (0.45) 0.992 (< 0.01) 0.051 (0.29) 0.112 (0.21) 0.780 (0.08) 0.035 (0.31) 0.999 (< 0.01) 0.233 (0.20) 3 months Median (IQR) 16.6 (8.3-24.8) 0.0 (0.0-33.0) 0.0 (0.0-8.3) 16.5 (11.0-27.8) 0.0 (0.0-16.5) 58.3 (37.4-79.3) 83.3 (75.0-91.7) 93.3 (86.7-100.0) 100.0 (83.3-100.0) 100.0 (100.0-100.0) 11.1 (0.0-33.3) 0.0 (0.0-0.0) 0.0 (0.0-0.0) n 38 5 38 35 40 11 46 46 46 46 46 46 46 Baseline Median (IQR) 8.3 (0.0-20.9) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 2.8 (0.0-11.0) 16.5 (0.0-33.0) 75.0 (66.6-87.6) 83.3 (75.0-91.7) 100.0 (93.3-100.0) 100.0 (83.3-100.0) 100.0 (87.5-100.0) 5.6 (0.0-22.2) 0.0 (0.0-0.0) 0.0 (0.0-0.0) n 41 6 41 38 42 23 50 50 50 50 50 50 50 QLQ-PR25 Urinary symptoms Incontinence aid (conditional) Bowel symptoms Hormonal treatment related symptoms Sexual activity Sexual functioning (conditional) QLQ-C30 Global quality of life Physical functioning Role functioning Social functioning Fatigue Pain Diarrhoea Legend: ADT = Androgen deprivation therapy. BL = Baseline. 3M = 3 months follow-up. 6M = 6 months follow-up. 12M = 12 months follow-up. IQR = Interquartile range. ES = Effect size. NA = Not available. Table S5 – QLQ-PR25 and QLQ-C30 outcome scores for the ADT group.
RkJQdWJsaXNoZXIy MTk4NDMw